當(dāng)前位置：首頁 SCI期刊 SCIE期刊醫(yī)學(xué) 中科院1區(qū) JCRQ1 期刊介紹(非官網(wǎng))

Journal Of Clinical OncologySCIE

國際簡稱：J CLIN ONCOL 參考譯名：臨床腫瘤學(xué)雜志

中科院分區(qū)
1區(qū)
CiteScore分區(qū)
Q1
JCR分區(qū)
Q1

基本信息：: ISSN：0732-183X; E-ISSN：1527-7755; 是否OA：未開放; 是否預(yù)警：否; TOP期刊：是

出版信息：: 出版地區(qū)：UNITED STATES; 出版商：American Society of Clinical Oncology; 出版語言：English; 出版周期：Biweekly; 出版年份：1983; 研究方向：醫(yī)學(xué)-腫瘤學(xué)

評(píng)價(jià)信息：: 影響因子：42.1; H-index：494; CiteScore指數(shù)：41.2; SJR指數(shù)：10.639; SNIP指數(shù)：6.162

發(fā)文數(shù)據(jù)：: Gold OA文章占比：29.96%; 研究類文章占比：96.87%; 年發(fā)文量：479; 自引率：0.0220...; 開源占比：0.254; 出版撤稿占比：0; 出版國人文章占比：0.05; OA被引用占比：0.1673...

投稿咨詢加急見刊

英文簡介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問題

英文簡介Journal Of Clinical Oncology期刊介紹

The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.

Print ISSN: 0732-183X

期刊簡介Journal Of Clinical Oncology期刊介紹

《Journal Of Clinical Oncology》自1983出版以來，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見解，或?qū)彶槎嗄陙砟硞€(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間：約2月
國際TOP期刊
醫(yī)學(xué)
ONCOLOGY
SCIE
中科院1區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Journal Of Clinical Oncology Cite Score數(shù)據(jù)

CiteScore：41.2
SJR：10.639
SNIP：6.162

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Oncology	Q1	9 / 404	97%
大類：Medicine 小類：Cancer Research	Q1	6 / 230	97%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標(biāo)來評(píng)價(jià)。

歷年Cite Score趨勢圖

中科院SCI分區(qū)Journal Of Clinical Oncology 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：否 Top期刊：是

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	1區(qū)	ONCOLOGY 腫瘤學(xué)	1區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國際、國內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開始，這個(gè)分區(qū)只是為了方便圖書管理及圖書情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢圖

JCR分區(qū)Journal Of Clinical Oncology JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ONCOLOGY	SCIE	Q1	6 / 322	98.3%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ONCOLOGY	SCIE	Q1	8 / 322	97.67%

JCR分區(qū)的優(yōu)勢在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢圖

發(fā)文數(shù)據(jù)

2023-2024 年國家/地區(qū)發(fā)文量統(tǒng)計(jì)

國家/地區(qū)數(shù)量
USA13290
Canada1872
CHINA MAINLAND1668
England1574
France1550
Japan1514
GERMANY (FED REP GER)1431
Italy1346
Spain1232
Australia922

本刊中國學(xué)者近年發(fā)表論文

1、Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)
Author: Peng, Zhenwei; Fan, Wenzhe; Zhu, Bowen; Wang, Guoying; Sun, Junhui; Xiao, Chengjiang; Huang, Fuxi; Tang, Rong; Cheng, Yu; Huang, Zhen; Liang, Yuchuang; Fan, Huishuang; Qiao, Liangliang; Li, Fuliang; Zhuang, Wenquan; Peng, Baogang; Wang, Jiping; Li, Jiaping; Kuang, Ming

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2023; Vol. 41, Issue 1, pp. 117-+. DOI: 10.1200/JCO.22.00392
2、Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial
Author: Zhang, Haiyan; Fan, Zhiping; Huang, Fen; Han, Lijie; Xu, Yajing; Xu, Na; Deng, Lan; Wang, Shunqing; Lin, Dongjun; Luo, Xiaodan; Zhang, Qing; Liu, Xiaodan; Li, Xudong; Liang, Xinquan; Xie, Shuangfeng; Qu, Hong; Yu, Sijian; Zhou, Hongsheng; Shi, Pengcheng; Xuan, Li; Lin, Ren; Liu, Hui; Jin, Hua; Sun, Jing; Liu, Qifa

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 343-+. DOI: 10.1200/JCO.22.00767
3、Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
Author: Drilon, Alexander; Subbiah, Vivek; Gautschi, Oliver; Tomasini, Pascale; de Braud, Filippo; Solomon, Benjamin J.; Tan, Daniel Shao-Weng; Alonso, Guzman; Wolf, Juergen; Park, Keunchil; Goto, Koichi; Soldatenkova, Victoria; Szymczak, Sylwia; Barker, Scott S.; Puri, Tarun; Bence Lin, Aimee; Loong, Herbert; Besse, Benjamin

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 385-+. DOI: 10.1200/JCO.22.00393
4、Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)
Author: Wang, Zhijie; Wu, Lin; Li, Baolan; Cheng, Ying; Li, Xiaoling; Wang, Xicheng; Han, Liang; Wu, Xiaohong; Fan, Yun; Yu, Yan; Lv, Dongqing; Shi, Jianhua; Huang, Jianjin; Zhou, Shaozhang; Han, Baohui; Sun, Guogui; Guo, Qisen; Ji, Youxin; Zhu, Xiaoli; Hu, Sheng; Zhang, Wei; Wang, Qiming; Jia, Yuming; Wang, Ziping; Song, Yong; Wu, Jingxun; Shi, Meiqi; Li, Xingya; Han, Zhigang; Liu, Yunpeng; Yu, Zhuang; Liu, An-Wen; Wang, Xiuwen; Zhou, Caicun; Zhong, Diansheng; Miao, Liyun; Zhang, Zhihong; Zhao, Hui; Yang, Jun; Wang, Dong; Wang, Yingyi; Li, Qiang; Zhang, Xiaodong; Ji, Mei; Yang, Zhenzhou; Cui, Jiuwei; Gao, Beili; Wang, Buhai; Liu, Hu; Nie, Lei; He, Mei; Jin, Shi; Gu, Wei; Shu, Yongqian; Zhou, Tong; Feng, Jian; Yang, Xinmei; Huang, Cheng; Zhu, Bo; Yao, Yu; Tang, Xiongwen; Yu, Jianjun; Maher, Ellen; Feng, Hui; Yao, Sheng; Keegan, Patricia; Wang, Jie

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2023; Vol. 41, Issue 3, pp. 651-+. DOI: 10.1200/JCO.22.00727
5、BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers
Author: Sun, Jie; Chu, Futao; Pan, Jiani; Zhang, Yaxin; Yao, Lu; Chen, Jiuan; Hu, Li; Zhang, Juan; Xu, Ye; Wang, Xiaojia; Cao, Wenming; Xie, Yuntao

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2023; Vol. 41, Issue 5, pp. 991-+. DOI: 10.1200/JCO.22.00833
6、Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
Author: Hillmen, Peter; Eichhorst, Barbara; Brown, Jennifer R.; Lamanna, Nicole; O'Brien, Susan M.; Tam, Constantine S.; Qiu, Lugui; Kazmierczak, Maciej; Zhou, Keshu; Simkovic, Martin; Mayer, Jiri; Gillespie-Twardy, Amanda; Shadman, Mazyar; Ferrajoli, Alessandra; Ganly, Peter S.; Weinkove, Robert; Grosicki, Sebastian; Mital, Andrzej; Robak, Tadeusz; Osterborg, Anders; Yimer, Habte A.; Salmi, Tommi; Ji, Meng; Yecies, Jessica; Idoine, Adam; Wu, Kenneth; Huang, Jane; Jurczak, Wojciech

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2023; Vol. 41, Issue 5, pp. 1035-+. DOI: 10.1200/JCO.22.00510
7、Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial
Author: Qin, Shukui; Chen, Zhendong; Fang, Weijia; Ren, Zhenggang; Xu, Ruocai; Ryoo, Baek-Yeol; Meng, Zhiqiang; Bai, Yuxian; Chen, Xiaoming; Liu, Xiufeng; Xiao, Juxiang; Ho, Gwo Fuang; Mao, Yimin; Wang, Xin; Ying, Jieer; Li, Jianfeng; Zhong, Wenyan; Zhou, Yu; Siegel, Abby B.; Hao, Chunyi

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2023; Vol. 41, Issue 7, pp. 1434-+. DOI: 10.1200/JCO.22.00620
8、Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial.
Author: Jiang J¹, Li Y¹, Shen Q^1,², Rong X¹, Huang X¹, Li H¹, Zhou L³, Mai HQ⁴, Zheng D⁵, Chen MY⁴, Xu Y¹, Li J⁴, Hui X⁶, Simone CB 2nd⁷, Gaertner J⁸, Argyriou AA⁹, Chow E¹⁰, Chen P³, Tang Y¹.

Journal: J Clin Oncol. 2019 Jan 10;37(2):135-143. doi: 10.1200/JCO.18.00896. Epub 2018 Nov 20.